期刊文献+

过氧化物酶体增殖物活化受体γ在大鼠非酒精性脂肪性肝炎肝纤维化形成中的作用 被引量:3

The role of PPARγ on the development of nonalcoholic steatohepatitis related fibrosis in rats
下载PDF
导出
摘要 目的研究大鼠非酒精性脂肪性肝炎(NASH)肝纤维化形成过程中肝组织核因子过氧化物酶体增殖物活化受体γ(PPARγ)的表达变化及意义。方法建立脂肪性肝纤维化大鼠模型,HE和Massson染色观察肝组织病理学变化,RT-PCR和免疫组织化学检测核转录因子PPARγ以及反映肝星状细胞(HSC)活化的特异性标记α-平滑肌肌动蛋白(α-SMA)的mRNA和蛋白表达变化。结果①模型组大鼠8w肝脏病理学呈现单纯性脂肪肝,12-16w呈现脂肪性肝炎,24w呈现脂肪性肝纤维化的病理学变化特点。②RT-PCR显示模型组PPARγ mRNA于高脂喂养8w即明显上调为0.84±0.07,对照组为0.54±0.12,P<0.05.12w达高峰为1.16±0.14,16w脂肪性肝炎明显时表达开始下调为0.73±0.05,24w下调更为明显为0.34±0.15,与对照组比较,差异均有统计学意义(P<0.05);而α-SMA mRNA于高脂喂养12w开始增高,24w达高峰,与对照组比较,差异均有统计学意义(P<0.01)。③免疫组织化学显示模型组PPARγ主要在脂肪变性的肝细胞核表达增高,在肝纤维化形成部位其阳性染色明显减少,而α-SMA阳性细胞主要在纤维间隔、汇管区等纤维形成区域表达增多。结论单纯性脂肪肝时,PPARγ的高表达可能是机体的一种适应性反应,随着高脂诱导的肝损伤程度的加重,PPARγ的表达逐渐降低与肝星状细胞的激活密切相关,从而促进脂肪性肝纤维化的发生、发展。 Objective To study the expression and significance of PPARγ in the development of nonalcoholic fatty liver fibrosis. Methods To establish a rat fatty liver fibrosis model by a high fat feeding,Hepatic expressions of PPARγ and α-SMA were observed by RT-PCR and immunohistochemistry.We also investigated the pathologic features and the degreed of liver fibrosis. Results (1)In the model group, liver pathology showed simple fatty liver (8 weeks) - steatohepatitis (12-16 weeks) - Fatty Liver fibrosis (24 weeks) of the characteristics of pathological changes. (2)RT-PCR showed that the expression of PPARγ mRNA were significance increased in the high fat diet for 8 weeks, Compared with the control group significantly (0.84±0.07 vs. 0.54 ± 0.12, P〈0.05), peaked in 12^th weeks (1.16± 0.14, P〈0.01),then decreased gradually at 16th week (0.73±0.05), 24 weeks decline obviously (0.34±0.15);and α-SMA mRNA increased at the 12^th week (0.46±0.19 vs 0.30±0.07, P 〈 0.05), peaked in 24th week (1.08±0.19); (3)Immunohistochemistry showed that in the model group PPARγ mainly in the fatty degeneration of the liver ceils increased expression, Liver fibrosis in positive staining were significantly reduced, and α-SMA-positive cells in the main fiber partitions, Exchange Zone fiber formation of regional expression increased. Conclusions Simple fatty liver, high- PPARγ expression of the body is an adaptive response, With the high fat-induced hepatic injury aggravated , the decreased gradually expression of PPARγ is closely related to the activation of hepatic stellate cells, thereby promoting the development of fatty liver fibrosis
出处 《药品评价》 CAS 2007年第4期298-302,共5页 Drug Evaluation
关键词 肝纤维化 非酒精性脂肪性肝炎 过氧化物酶体增殖物活化受体Γ Α-平滑肌肌动蛋白 Liver Fibrosis Nonalcoholic Steatohepatitis Peroxisome Proliferation activated receptor gamma α-Smooth Muscle Actin
  • 相关文献

参考文献8

  • 1Abdelrahman M;Sivarajah A;Thiemermann C.Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury,inflammation and shock[J],2005.
  • 2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1513
  • 3Diehl AM.Lessons from animal models of NASH[J],2005.
  • 4He G;Sung YM;Fischer SM.Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes[J],2006.
  • 5Emma LH;Steven J;Tucker CJ.Pregnane Ⅹ Receptor Activators Inhibit Human Hepatic Stellate Cell Transdifferentiation In Vitro[J],2006(1).
  • 6Rollins MD;Sharon S;Matthew A.Anti-inflammatory Effects of PPAR-γ Agonists Directly Correlate With PPAR-γ Expression During Acute Pancreatitis[J],2006(8).
  • 7Inoue M;Ohtake T;Motomura W.Increased expression of PPARγin high fat diet-induced liver steatosis in mice[J],2005(1).
  • 8Kawaguchi K;Sakaida I;Tsuchiya M.Pioglitazone prevents hepatic steatosis,fibrosis,and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient -amino acid-defined diet[J],2004.

二级参考文献18

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1512

同被引文献60

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部